Acute Kidney Injury and Acute Liver Failure in Leptospira Infection and Weil’s Syndrome by Chávez-Iñiguez,  Jonathan S et al.
 Journal of Renal and Hepatic Disorders 2020;4(2):21–28 21
Journal of  Renal and Hepatic Disorders
REVIEW NEPHROLOGY
Acute Kidney Injury and Acute Liver Failure in Leptospira Infection 
and Weil’s Syndrome
Jonathan S Chavez-Iniguez1,2, Said Cabrera-Aguilar1, Guillermo Garcia-Garcia1,2,  
Juan Armendariz-Borunda2,3
1Nefrology Seravice, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico; 2University of Guadalajara Health 
Sciences Center (CUCS), Guadalajara, Jalisco, Mexico; 3Tecnologico de Monterrey, Campus Guadalajara, Mexico
Abstract
Leptospirosis is considered a zoonosis acquired predominantly from contaminated surfaces and water, more commonly in emerging countries 
with limited sanitary conditions. Leptospira in the host unleashes an immune response that explains the symptoms and clinical signs; once it 
reaches the kidney and liver tissue, it can manifest with alterations that lead to acute and chronic diseases in both organs. Weil’s syndrome is the 
best known clinical manifestation with jaundice and acute kidney injury that could lead to multiple organ failure and death. For its diagnosis, 
there are simplified scores such as the SPiRO score, the microbiological criteria by microscopy or serological tests; the treatment focuses on 
antibiotics and, if  necessary, provides organic support until the infection is curtailed. The purpose of this review was to address the impact of Lep-
tospira infection on the kidney and liver, the mechanisms of organ damage, the clinical presentation, and diagnosis and management of this disease.
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Introduction
Leptospira shares characteristics of both gram-positive and 
gram-negative bacteria, and it is strictly a gram-negative aer-
obic bacterium belonging to the spirochetes genus. There are 
22 species (pathogenic and nonpathogenic), as well as more 
than 350 serotypes (1) (Figure 1A). Leptospira was first 
observed more than 100 years ago and has been found in 
most mammals worldwide, including a kidney sample from 
a whale (2). It is transmitted to humans via infected animals 
when they come in contact with, or through, contaminated 
water. It is a ubiquitous disease, more commonly found in 
tropical climates and in areas where large reservoirs of stag-
nant water accumulate (3), such as lakes or water remnants 
from natural disasters (4) (Figure 1B), and transplacental 
infection is rare but possible (5).
It can result in conditions ranging from a mild and clin-
ically irrelevant disease, to multi-organ failure, with a high 
mortality rate. In this review, we will describe the epidemio-
logical and clinical aspects of renal and hepatic involvement.
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co-exist within the same environment. Therefore, monitor-
ing of potentially contaminated areas is found to have public 
health benefits, thanks to the impact of maintaining a high 
degree of diagnostic suspicion when outbreaks of patho-
genic strains occur, as well as keeping track of antibiotic sus-
ceptibility reports (12).
Pathophysiology
Infection in humans usually occurs via mucous membranes 
or skin abrasions through which microorganisms penetrate 
the body (Figure 1C). Once inside, the bacteria enter into 
the lymphatics and then into the blood stream. From the 
bloodstream, the infection can spread systemically but tends 
to settle down within the liver and the kidneys (13). Some 
studies suggest that the clinical course of the disease depends 
on a relationship between the species, inoculum size and the 
route of infection, and the clinical course and outcomes of 
the  disease (4, 14).
Leptospira interrogans produces endotoxins that affect 
the tubulointerstitial cells, and contains lipopolysaccharide, 
cytotoxic glycolipoprotein (GLP), and lipoprotein (LipL), 
especially LipL32, which is immunogenic, and has the ability 
to activate the immune response driven by white blood cells, 
producing tumor necrosis factor-α and/or proinflammatory 
interleukins (15).
Epidemiology
The incidence of leptospirosis is 10–100 cases per 100,000 
population/year in humid tropics. However, the incidence 
appears to be higher, with some studies reporting a sero-
prevalence of anti-Leptospira antibodies of up to 33% in 
asymptomatic individuals. The World Health Organization 
has included leptospirosis as a re-emerging infectious dis-
ease, and cases have been increasingly reported in developed 
countries, where rodents, dogs, pigs, cattle, and horses are the 
typical vectors (6, 7) (Figure 1B). As of 2015, the global inci-
dence of leptospirosis amounted to 1.03 million cases annu-
ally, with 58,900 deaths worldwide (8).
The route of infection in animals is usually the same as 
that in humans, that is, through direct or indirect contact 
with tissues, urine, soils, or water contaminated by a pre-
viously infected individual. When the organism is passed 
through the infected animal’s urine, it can survive in fresh 
water for up to 16 days, and in soil for almost 24 days (9, 10). 
Therefore, exposure to animals typical of this area, as well 
as activities related to water tanks, are risk factors. Patients 
with a flooded workplace have a high probability of expo-
sure to the infective organism for a longer duration than 
other locations (11)  (Figure 1C). Because of factors such 
as population growth and poor health conditions, there has 
been an increase in the incidence of this disease. In addition, 
it has been reported that different types of Leptospira can 
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Figure 1. Transmission of Leptospira and the development of leptospirosis with its clinical manifestations: (A) Leptospira are 
strictly anaerobic bacteria belonging to the spirochetes genus; (B) Leptospira in infected rodents, dogs, pigs, cattle, and horses 
are the typical vectors; (C) The route of infection is through direct or indirect contact with contaminated tissues, urine, soils or 
water; (D) The incubation period is usually 8–12 days; (E) Pathophysiological and clinical manifestations of leptospirosis and 
the Weil’s syndrom.
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and may require liver transplantation (32). The presence 
of  conjunctival icterus, increased creatinine phosphokinase 
(CPK) levels, and less severe transaminitis suggests the pres-
ence of  Weil’s syndrome, rather than acute liver failure of 
a different etiology  (33). Pulmonary manifestations and a 
state of  shock add to the severity to the clinical syndrome. 
Mortality can be associated with advanced age, shock, 
bleeding, steroid use, oliguria, and arrhythmias. The rate 
of  mortality can be reduced with timely administration of 
antibiotic treatment (9, 34). In the presence of  thrombo-
cytopenia, platelet aggregation and phagocytosis of  the 
Kupffer cells should be considered before disseminated 
intravascular coagulation (35). Although rare, autoimmune 
hemolytic anemia may appear (27) (Figure 1E). Mortality is 
significantly higher in older patients with icteric disease or 
renal failure but is lower in younger, anicteric patients (36). 
There is definite cardiac involvement in leptospirosis, 
which, although not symptomatically evident, may add to 
the morbidity and mortality or contribute to the mortality 
associated with the disease (37). In patients with severe lep-
tospirosis in tropical Australia, prompt intensive care unit 
(ICU) support, including early antibiotic administration, 
protective ventilation strategies, cautious fluid resuscitation, 
traditional thresholds for renal replacement therapy initia-
tion, and corticosteroid therapy, was associated with a very 
low case- fatality rate (38). Pulmonary involvement at admis-
sion is a strong predictor of  mortality among patients with 
severe leptospirosis (39). There have been reports on the use 
of  veno-venous extracorporeal membrae oxygenation in 
cases with severe respiratory failure and pulmonary hemor-
rhage, continuous renal replacement therapy in acute kidney 
injury (AKI), as well as plasmapheresis and extracorporeal 
cytokine absorbent  therapy (40, 41).
The presence of multi-organ dysfunction syndrome and 
serum potassium concentration >5.0 were independently 
associated with mortality in patients with confirmed lepto-
spirosis in a critical care setting (42).
Manifestations in the kidney
In the kidney, the clinical manifestations vary widely from 
disorders of urine concentration and electrolytes abnormali-
ties, to AKI and chronic kidney disease (CKD).
The Leptospiral GLP appears to influence tubular trans-
port of ions, particularly Na+ and K+ (43). GLP is a potent 
and specific Na/K-ATPase inhibitor (44). Tubular changes, 
characterized by high urinary fractional excretion of sodium 
and potassium, precede the decrease in glomerular filtra-
tion rate, which could explain the high prevalence of hypo-
kalemia. Given that hypomagnesemia usually occurs in 
the first phase of the disease, close monitoring is also rec-
ommended (45). Tubulointerstitial nephritis is a common 
finding in leptospirosis. In his 2010 report, Araujo et al. 
The host immune response is both humoral and cellular, 
and “cytokine storm” and “immunosuppression” models 
have been proposed (16). Although the pathophysiology 
of leptospirosis consists of a particular network of mech-
anisms that are not fully understood, there is no reason 
to consider the septic shock it causes as different from the 
typical septic shock caused by other bacteria (17). Markers 
of endothelial activation and immune activation were asso-
ciated with disease severity in leptospirosis patients, and 
it has been shown that plasma levels of E-selectin and Von 
 Willebrand Factor (VWF) strongly increased  (18). Lepto-
spires can pass between epithelial cells, including those lin-
ing the renal tubules, and this could be an important way to 
reach and colonize the lumen of the proximal tubules. They 
have the ability to adhere to cell adhesion molecules, mem-
brane proteins, and transmembrane glycoproteins of the 
endothelium necessary to maintain vascular integrity, which 
is a pathogenic mechanism on the endothelium itself  (which 
includes the glomerular, cardiac, and hepatic endothelium). 
Damage to the glycocalyx has also been observed in kidney 
tissue obtained from infected individuals (19). The damage 
to the endothelium may be a key factor in pulmonary pathol-
ogy. By promoting the extravasation of immune cells to the 
pulmonary alveoli, autoimmune damage may be triggered, 
which can cause pulmonary edema and hemorrhagic mani-
festations (19).  Furthermore, although most electron micros-
copy findings are nonspecific and may be related to the sepsis 
manifestations of the disease, they suggest a marked alter-
ation of the cell membrane (19).
Weil’s syndrome
Following an incubation period of 7–12 days, clinical manifes-
tation of leptospirosis ranges from mild febrile syndrome to 
multi-organ failure (16, 20). Other less specific symptoms, 
which are reported less frequently, include muscle aches, 
headaches, colds, and mucosal hemorrhage (21) (Figure 1D 
and 1E), including influenza (22), pancreatitis (23), and 
gastrointestinal symptoms, with vomiting and diarrhea, 
and fatal septic shock (21). There are reports of  neurolog-
ical symptoms such as aseptic meningitis, reversible poste-
rior encephalopathy (24), and focalization symptoms due 
to intracerebral thrombosis (25) (Figure 1D and 1E). The 
simultaneous development of  hepatic and renal failure, 
together with hemorrhagic complications (highly severe 
when they occur in the lungs), is called Weil’s syndrome 
(26,  27), and represents the severe phase of  leptospirosis. 
Weil’s syndrome carries a mortality rate between 5% and 
15% of the cases (22, 28, 29). Clinically, it presents as an 
icteric fever and myalgia, with multi-organ involvement (9). 
In addition to being caused by co-infections with other liver- 
damaging agents (30), fulminant hepatic failure appears 
to be linked to endothelial damage in the liver sinuses (31) 
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observed a decrease in the expression of ATPase of NHE 3, 
aquaporin-1, and α-Na (+) K (+) ATPase in the cells of the 
proximal convoluted tubule. The expression of aquaporin-1 
was preserved along the thin descending limb of Henle’s 
loop in the outer medulla. The expression of α-Na (+) K (+) 
ATPase was essentially preserved in the distal tubules, that is, 
the thick ascending limb of the Henle’s loop, macula densa, 
and distal convoluted tubule. The expression of aquaporin 2 
in the collecting tubules was enhanced compared with that 
in the nonleptospirotic kidneys. NKCC2 cotransport iso-
form was expressed in the thick ascending limb of  Henle’s 
loop and was essentially preserved in the leptospirotic 
 kidneys  (46).  Primary injury of the proximal convoluted 
tubules is regarded as the hallmark of the kidney in lepto-
spirosis (47). Sodium and water transport are particularly 
affected with increased distal potassium excretion, hypokale-
mia, and polyuria (46).
Kidney injury secondary to rhabdomyolysis and pyelo-
nephritis has also been found. It should be suspected when 
treating patients with AKI and hyperbilirubinemia (47) who 
have recently traveled to tropical countries or considered as 
a differential diagnosis in children with acute fever of infec-
tious origin, with its focus yet to be determined (48).
AKI is the most frequent complication in Weil’s disease, 
and it is caused by a combination of acute tubular necrosis 
(ATN) and tubulointerstitial nephritis (49). The incidence of 
leptospirosis-associated AKI is up to 80%, and its severity is 
associated with increasing mortality (50, 51, 52, 53). Indepen-
dent risk factors for ICU admission include tachypnea, hypo-
tension, and AKI. Ceftriaxone is a protective factor for ICU 
admission, suggesting that its use may prevent severe forms of 
the disease (54). AKI is typically nonoliguric and is associated 
with hypokalemia. Oliguria, jaundice, and arrhythmias have 
been shown to be predictors of AKI development. Hypoka-
lemia is commonly observed in tubulointerstitial nephritis 
(55). During AKI, a Toll-Like receptors (TLR-2)-dependent 
immune response occurs, triggering inflammation, which can 
progress to fibrosis (56). Although acute leptospirosis does 
not induce multi-organ dysfunction, it can be a predisposing 
factor for progression to CKD if not treated early. CKD can 
cause proximal tubular dysfunction, which can be observed 
in agricultural workers with asymptomatic chronic leptospi-
rosis. It has been suggested that this could represent a pre-
disposing factor that only needs a second hit, such as heat 
stress or severe dehydration, to progress to end-stage renal 
disease  (57). Another hypothesis supporting leptospirosis 
as a cause of CKD is the recurrence of AKI, hypokalemia, 
and the constant proinflammatory stimulus; as an example, 
some authors have considered it as a possible risk factor in 
chronic kidney disease of unknown etiology (CKDu). In spite 
of evidence suggesting that there is an association between 
leptospirosis and CKDu, no definitive conclusions have been 
drawn as yet (58) (Figure 1E).
Manifestation in the Liver
In icteric leptospirosis, characterized by rapidly progressive 
clinical course, high serum bilirubin levels together with 
moderate increase in liver transaminases may occur (20). 
Of all leptospiral cases, 5%–10% develop a severe form of 
icterus (26), which is associated with a mortality rate of 
5%–15% (59). It remains unclear to what degree the over-
all liver function is diminished in icteric leptospirosis (59). 
Bilirubin and other commonly used parameters of hepatic 
function, such as aminotransferases, albumin, or prothrom-
bin time, are static estimates that cannot assess complex liver 
functions such as clearance of substances or formation of 
metabolites (60). Approximately, 90% of Leptospira infec-
tions present with nonspecific anicteric clinical picture of 
fever, which self-limits within a few days. It can later recur 
as an immune phase (in this phase, aseptic meningitis can 
occur), when anti-Leptospira antibodies appear (and bacte-
ria can appear via excreted urine) (56) (Figure 1E).
Diagnostic Tests
In the mild form of leptospirosis, routine blood tests results 
are usually nonspecific (26). In adults with leptospirosis, a 
simple three-point clinical score—the SPiRO score—appears 
to reliably identify patients at risk of severe disease. An 
absence of hypotension, oliguria, or abnormal auscultatory 
findings—a SPiRO score of zero—was particularly helpful in 
identifying patients at low risk of severe disease. This score 
facilitates the recognition of high-risk patients, expediting 
the initiation of supportive treatment, and prompting con-
sideration to transfer to a referral facility (61).
Since diagnostic methods can be direct or indirect, the best 
method depends on when it is used (62) (Figure 2). There are 
various diagnostic methods: those based on microbiology (dark-
field microscopy), serology (microscopic agglutination test 
[MAT], enzyme-linked immunosorbent assay [ELISA], immu-
nofluorescence, hemagglutination, and lateral flow assay), and 
those based on molecular biology. MAT is the gold standard for 
serodiagnosis of leptospirosis because of its unsurpassed diag-
nostic specificity (63, 64). A combination of C-reactive protein 
(CRP) and ELISA has been proposed to achieve a rapid diag-
nosis with little margin for error; however, MAT should sub-
sequently be used to identify the serotype for epidemiological 
purposes (63).
The modified Faine’s prediction score is limited by the 
requirement of specialized tests, which are difficult to con-
duct in rural areas. In addition, it was developed for patients 
who required hospitalization. Because of the high preva-
lence of leptospirosis in rural areas of developing countries 
(up to 29.5% in high-risk groups) (65) and the lack of the 
required infrastructure to carry out these tests, a new score, 
the OPD Lepto score, has been developed. It comprises only 
Weil’s syndrome
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However, a recent study failed to show a decrease in mor-
tality in leptospirotic patients receiving empiric antibiotics 
(28, 71). Although Leptospira spp. are intrinsically resistant 
to several antibiotics, there is little evidence of acquired resis-
tance to antimicrobial agents used in the treatment of acute 
leptospirosis (1). Patients experience shaking chills, a rise in 
temperature, and intensification of skin rashes known as the 
Jarisch–Herxheimer reaction (JHR), with symptoms resolv-
ing a few hours later. Case reports indicate that the JHR can 
also include uterine contractions in pregnancy, worsening of 
liver and renal function, acute respiratory distress syndrome, 
myocardial injury, hypotension, meningitis, alterations in 
consciousness, seizures, and stroke (72). Two risk factors were 
independently associated with JHR occurrence: L. interro-
gans serogroup Australis as the infectious agent and a delay 
of >3 days between the onset of symptoms and the initiation 
of antibiotherapy (73). Although rarely encountered and 
not well described in the literature, initiation of antibiotics 
can cause a JHR reaction. The JHR may be self-limited and 
of short duration, or it can be prolonged and severe (74). It 
has been recommended that patients started on antibiotics 
for leptospirosis/Weil’s disease should be monitored in the 
emergency department for a short period of time, prior to 
discharge or being admitted to a regular medical ward for 
observation, given the possibility of decompensation. The 
use of azithromycin and doxycycline has been shown to 
decrease seropositivity without a significant effect on clinical 
leptospirosis (65).
The treatment of Weil’s syndrome consists of life support 
measures and antibiotic therapy (75). It is common for seri-
ously ill patients to require renal support therapy and ICU 
five items, which are accessible to the primary care physician, 
and is feasible in outpatient settings. The maximum score is 
7, with 3.5 being the cutoff  point to identify patients at high 
risk of having leptospirosis, requiring prompt intervention to 
treat the disease (11).
The LeptoDB database incorporates data on genetics, 
immunology, and possible therapeutic targets (21). Kunikow-
ska et al. described a case of hepatic failure, where dynamic 
tests, such as indocyanine green plasma (ICG) clearance, 
reflected more the hepatic functional status. Prolonged ele-
vation in serum bilirubin levels may not adequately reflect 
recovery of liver injury in this disease. ICG clearance appears 
to be a promising marker for the detection of hepatic dys-
function and recovery in icteric leptospirosis (66).
Treatment
An approach and treatment algorithm are proposed in 
 Figure  2. Antibiotic treatment is considered efficient in all 
stages of the disease. Mild cases can be treated in the out-
patient setting with oral amoxicillin (30–40 mg/kg/day) or 
ampicillin (50–100 mg/kg/day) four times a day for 7–10 days. 
Children > 8 years of age can receive doxycycline (2 mg/kg/
dose) two times a day for 7–10 days (62, 63, 67–69). Patients 
with severe infections should be treated with intravenous pen-
icillin in doses of 50,000–100,000 U/kg/day for 7–10 days, or 
with third-generation cephalosporins or erythromycin (9). 
In patients allergic to penicillin, erythromycin, 30–50 mg/kg/
day, can be given in 3–4 doses for 7–10 days. Empiric treat-
ment should be recommended before confirmation of labo-
ratory tests, as serological diagnosis is time-consuming (70). 
First
evaluation
OPD Lepto
Score >3.5 No
Observation
Yes
No Discard another
disease
Consider ICU
No
Empirical treatment with
penicillin, erythromycin,
ampicillin, amoxicillin,
ceftriaxone or doxycycline
ELISA IgM from day 3
or MAT from day 5 of
symptoms
Positive
result
Yes
Yes
SPiRo ³ 2
Figure 2. The diagnostic/treatment algorithm for patients at high risk of acquiring leptospirosis, defined as an OPD Lepto Score 
> 3.5.
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monitoring. Treatment recommendations include a high dial-
ysis dose, but the type of dialysis may not affect clinical out-
comes in severe leptospirosis (76). Conservative fluid intake 
and approaches to minimize lung injury, such as low tidal 
volume and high positive end-expiratory pressure, when arti-
ficial ventilation is required, are recommended (28, 77).
Finally, Gomes et al. opened a new window of opportu-
nity to treat leptospirosis with antibodies. They reported that 
anti-LipL32 mAbs inhibited the growth of L. interrogans 
in vitro and offered significant protection in animal models 
when administered prior to infection (78).
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